Summary:
Meridien Research is conducting a new research study for the treatment of Secondary Progressive Multiple Sclerosis utilizing the investigational medication, Tcelna©, a personalized immunotherapy manufactured for individual patients.
Qualified participants will receive at no cost study-related:
- Evaluations, physical exams, routine lab work
- Investigational medication or placebo
Compensation for time and travel may be available. No medical insurance is necessary.